Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa

  1. Liyun Zhang
  2. Conan Chen
  3. Jie Fu
  4. Brendan Lilley
  5. Cynthia Berlinicke
  6. Baranda Hansen
  7. Ding Ding
  8. Guohua Wang
  9. Tao Wang
  10. Daniel Shou
  11. Ying Ye
  12. Timothy Mulligan
  13. Kevin Emmerich
  14. Meera T Saxena
  15. Kelsi R Hall
  16. Abigail V Sharrock
  17. Carlene Brandon
  18. Hyejin Park
  19. Tae-In Kam
  20. Valina L Dawson
  21. Ted M Dawson
  22. Joong Sup Shim
  23. Justin Hanes
  24. Hongkai Ji
  25. Jun O Liu
  26. Jiang Qian
  27. David F Ackerley
  28. Baerbel Rohrer
  29. Donald J Zack
  30. Jeff S Mumm  Is a corresponding author
  1. Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, United States
  2. The Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University, United States
  3. Department of Biostatistics, Johns Hopkins University, United States
  4. School of Chemistry, Xuzhou College of Industrial Technology, China
  5. College of Light Industry and Food Engineering, Nanjing Forestry University, China
  6. Department of Genetic Medicine, Johns Hopkins University, United States
  7. School of Biological Sciences, Victoria University of Wellington, New Zealand
  8. Department of Ophthalmology, Medical University of South Carolina, United States
  9. Department of Neurology, Johns Hopkins University, United States
  10. Institute for Cell Engineering, Johns Hopkins University, United States
  11. Department of Pharmacology and Molecular Sciences, Johns Hopkins University, United States
  12. Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, United States
  13. Faculty of Health Sciences, University of Macau, Taipa, China
  14. Department of Oncology, Johns Hopkins University, United States
  15. Department of Molecular Biology and Genetics, Johns Hopkins University, United States
11 figures, 4 tables and 3 additional files

Figures

Figure 1 with 1 supplement
Zebrafish-inducible RP model and schematic of large-scale phenotypic screen.

(A–C) Prodrug (Metronidazole, Mtz) inducible ablation of rod photoreceptors in rho:YFP-NTR larvae. (A) In vivo confocal images of a rho:YFP-NTR larvae showing transgene expression specificity and …

Figure 1—figure supplement 1
Immunohistological labeling of rod and cone photoreceptors in rho:YFP-NTR larvae.

(A–C) Immunohistological analysis of rod and cone photoreceptor markers in seven dpf rho:YFP-NTR larvae retinas treated ± 2.5 mM Mtz from 5 to 7 dpf. Representative whole retina and zoomed images of …

Figure 2 with 3 supplements
Confirmation of neuroprotective effects of lead compounds in rho:YFP-NTR zebrafish larvae.

(A) Diagram of confirmation assay protocol (see Figure 1D for further details). (B) Box plots of rod cell survival effects of eleven confirmed lead compounds (arrayed by level of neuroprotection) …

Figure 2—figure supplement 1
Test of lead compound effects on NTR enzymatic activity.

(A) Box plots of NTR inhibition activity (relative to NTR alone control, set at 100%) of lead compounds tested at 300 or 50 μM (see B) using an in vitro assay of CB1954 prodrug reduction kinetics. …

Figure 2—figure supplement 2
Test of lead compound effects on rod cell neogenesis during development.

(A) Diagram of rod cell neogenesis assay protocol. Transgenic rho:YFP-NTR larvae were treated with individual lead compounds from 5 to 7 dpf to test for effects on rod photoreceptor neogenesis; …

Figure 2—figure supplement 2—source data 1

Compound effects on rod cell neogenesis.

https://cdn.elifesciences.org/articles/57245/elife-57245-fig2-figsupp2-data1-v4.xlsx
Figure 2—figure supplement 3
Test of lead compound effects on rod cell regeneration.

(A) Diagram of rod cell regeneration assay protocol. Transgenic rho:YFP-NTR were exposed to 10 mM Mtz from 5 to 6 dpf, then treated with individual lead compounds from 6 to 9 dpf. YFP signals were …

Figure 2—figure supplement 3—source data 1

Compound effects on rod cell regeneration.

https://cdn.elifesciences.org/articles/57245/elife-57245-fig2-figsupp3-data1-v4.xlsx
Figure 3 with 2 supplements
Confocal imaging of neuroprotective effects of confirmed lead drug compounds.

Representative 7 dpf in vivo confocal images of YFP-expressing rod cells in an ablated control (+Mtz), non-ablated control (-Mtz), and in Mtz-exposed retinas treated with lead compounds from 5 to 7 …

Figure 3—figure supplement 1
Quantification of YFP intensity in Figure 3 confocal images.

Box plots of lead compound effects on YFP volumes per image stack across conditions. All conditions resulted in a statistically significant increase in YFP volume relative to Mtz-ablated controls. …

Figure 3—figure supplement 2
Lead compound effects on outer segment morphology.

(A) Representative 7 dpf in vivo confocal images of YFP-expressing rod cells in an ablated control (+Mtz), non-ablated control (-Mtz), and in Mtz-exposed rho: YFP-NTR2.0 retinas treated with lead …

Figure 3—figure supplement 2—source data 1

YFP quantification - volume per cell.

https://cdn.elifesciences.org/articles/57245/elife-57245-fig3-figsupp2-data1-v4.xlsx
Figure 4 with 2 supplements
Lead effects pn mouse primary photoreceptor cells - thapsigargin-induced cell death.

(A) Primary photoreceptor survival assay protocol. (B) Box plots of photoreceptor survival effects of lead compounds and the positive control compound (POS). Statistically significant survival …

Figure 4—source data 1

Compound tests of mouse photoreceptor culture - thapsigargin assay.

https://cdn.elifesciences.org/articles/57245/elife-57245-fig4-data1-v4.xlsx
Figure 4—figure supplement 1
Lead effects on mouse photoreceptor cultures - tunicamycin-induced cell death.

A) Diagram of primary photoreceptor survival assay protocol. Primary retinal cells were isolated from QRX mice and cultured for 2 days in tunicamycin (an ER stressor that induces cell death) and …

Figure 4—figure supplement 1—source data 1

Quantification of mouse photoreceptor assay - tunicamycin-induced cell death.

https://cdn.elifesciences.org/articles/57245/elife-57245-fig4-figsupp1-data1-v4.xlsx
Figure 4—figure supplement 2
Paired lead compound survival effects in mouse photoreceptor cultures.

(A–B) Lead compounds were tested individually and in pairs for survival effects in primary photoreceptor cells isolated from QRX mice as per Figure 4. Box plots and summary tables (below plots) show …

Figure 4—figure supplement 2—source data 1

Paired drug tests - mouse photoreceptor cultures.

https://cdn.elifesciences.org/articles/57245/elife-57245-fig4-figsupp2-data1-v4.xlsx
Lead effects on mouse rd1 retinal explant cultures.

(A) Diagram of rd1 explant photoreceptor survival assay protocol. Retinal explants were isolated at postnatal day 10 (P10) and cultured for eleven days in lead compounds at three different …

Test of long-release DHA formulation in the rd10 mouse model of RP.

(A) In vitro release kinetics of a long-release DHA formulation (DHA encapsulated in PLGA polymer microparticles, PLGA-DHA) in phosphate buffered saline containing 0.1% DMSO (pH 7.4) at 37°C (Figure …

Figure 7 with 1 supplement
Chemical inhibitor analysis of NTR/Mtz-mediated rod cell death in zebrafish.

Box plots of rod cell survival effects of eight PARP inhibitors (green), a necroptosis inhibitor (blue), four apoptosis inhibitors (magenta), and three Tdp1 inhibitors (orange) in Mtz-treated rho:YFP…

Figure 7—figure supplement 1
Additive survival effects of paired PARP and necroptosis inhibitors.

Box plots of rod cell survival effects of BMN (PARP inhibitor) and NEC (necroptosis inhibitor) tested alone and in pairs at three different concentrations in rho:YFP-NTR zebrafish larvae (assays …

Figure 8 with 1 supplement
Genetic knockdown analysis of NTR-mediated rod cell death pathways in zebrafish.

(A) Box plots of rod cell survival effects of CRISPR/Cas9-based knockdown of key cell death pathway genes: parp1 (parthanatos), ripk1l (necroptosis), casp3a and casp3b (apoptosis), as well as tdp1

Figure 8—figure supplement 1
Genetic and biochemical analysis of NTR-mediated rod cell death in zebrafish.

(A) Representative intravital whole retina confocal image stacks of gene knockdown effects on YFP-expressing rod cell numbers in Mtz-treated fish (+Mtz, i.e. effects on NTR/Mtz-mediated cell death) …

Test of lead compound survival effects in parp1 knockdown zebrafish larvae.

(A) Box plots of rod cell survival effects of five lead compounds and a PARP inhibitor control (BMN) in Mtz-treated rho:YFP-NTR zebrafish larvae in which parp1 expression was knocked down, assays …

Additive survival effects of paired lead compounds in zebrafish RP model.

Box plots of rod cell survival effects of seven lead compounds tested alone and in pairs in rho:YFP-NTR zebrafish larvae (assays performed as per confirmation tests, see Figure 2A). To test for …

Summary.

(A) Flow chart of cross-species phenotypic drug discovery process showing results of the primary drug screen, secondary confirmation, orthogonal assays, mouse model tests, shared MOA and …

Tables

Table 1
Eleven confirmed lead compounds.

Common names, IUPAC names, abbreviations, PubChem CID, and chemical structures of confirmed lead compounds listed in order of efficacy.

Common and IUPAC namesAbbr.PubChem CIDStructure
Warfarin
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
WAR54678486
Cloxyquin 5-Chloro-8-hydroxyquinolineCLO2817
Ciclopirox olamine
2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
CPO38911
Miconazole
1-[2-(2,4-dichlorophenyl)−2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
MIC4189
Zinc pyrithione zinc;1-oxidopyridin-1-ium-2-thiolateZPT26041
Dihydroartemisinin
(4S,5R,9R,10S,12R,13R)−1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
DHA456410
Chloroxine
5,7-dichloroquinolin-8-ol
CHL2722
Calcimycin
5-(methylamino)−2-[[(2S,3R,5R,8S,9S)−3,5,9-trimethyl-2-[1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]−1,7-dioxaspiro[5.5]undecan-8-yl]methyl]−1,3-benzoxazole-4-carboxylic acid
CAL40486
Sulindac
2-[(3Z)−6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
SUL1548887
Artemesinin
(1R,4S,5R,8S,9R,12S,13R)−1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
ART68827
Cortexolone
(8R,9S,10R,13S,14S,17R)−17-hydroxy-17-(2-hydroxyacetyl)−10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
COR440707
Table 2
Summary of PubChem HTS and uHTS target-based screens of lead compound bioactivity.

Results of 13 target-based HTS screens, with '+' indicating inhibitory activity of lead compounds. Lead compound abbreviations: WAR, Warfarin; CLO, Cloxyquin; CPO, Ciclopirox olamine; MIC, …

Drug\pathTdp1RorcARTRVDRERAhRGRP53DopaHIF1SHHCOX
WAR+
MIC+++++
CLO+++++++
CPO+++++++++
ZPT++++++++++
DHA++++
CHL+++++++++
CAL+++
SUL+++
ART++
COR++
Table 3
Chemical inhibitors of lead implicated targets and cell death pathways.

List of eight PARP inhibitors, one necroptosis inhibitor, three apoptosis inhibitors, and three TDP1 inhibitors tested for neuroprotective effects in rho:YFP-NTR larvae (see Figure 4 and Figure …

Cell death
Pathway
Compound name (abbrv.)Target(s) and Relative Activity (+)Conc.
[µM]
Effect
(%)
Parp-dependent
(Parthantos or cGMP-dependent)
AG-14361 (AG)Parp1+++649
NMS-P118 (NMS)Parp1++816
Talazoparib (BMN)Parp1 ++++0.514
Veliparib (ABT)Parp1+++, 2+++649
Olaparib (Ola)Parp1+++, 2++++329
E7449Parp1++++, 2++++120
Niraparib (MK)Parp1+++, 2+++3211
Rucaparib (RUC)pan-Parp++++3217
NecroptosisNecrostatin-1 (NEC)Rip1k++6417
ApoptosisAc-DEVD-CHO (AC)Caspase 1+++, 2+, 3++++, 4++, 5++, 6+++, 7+++, 8++++, 9++, 10+++0.53
Caspase3/7 inhibitor I (CASI)Caspase 3++, 7++, 9+0.51
Caspase three inhibitor VII (CASVII)Caspase 3+++12
Tdp1
(DNA repair)
Paromomycin (PM)Tdp1+2010
Thiostrepton (ThS)Tdp1+10010
Methyl-3,4-dephostatin (MD)Tdp1++0.163
Key resources table
Reagent type
(species) or resource
DesignationSource or reference
Transgenic zebrafish, Danio rerio (AB; roy)Tg(rho:YFP-Eco.NfsB)gmc500; mpv17a9
(rho:YFP-NTR)
RRID # #:ZFIN_ZDB-GENO-190617–10
Transgenic zebrafish
Danio rerio (AB; roy)
Tg(rho:GAP-YFP-2A-nfsB_Vv F70A/F108Y)jh405; mpv17a9 (rho:YFP-NTR2.0)ZFIN ID pending; Mumm lab
E. coliBL21(DE3) Competent Cellsemdmillipore.com: 69450
Mutant mouse
Mus musculus
Pde6brd1
(rd1)
RRID #:MGI:5902961
Mutant mouse
Mus musculus (C57BL/6J)
Pde6brd10
(rd10)
RRID # #:IMSR_JAX:004297
Transgenic mouse
Mus musculus (SJL/J)
QRX-IRES-EGFPZack lab
AntibodyAnti-Arrestin3a (α-Arr3a; zpr-1)
Mouse monoclonal (1:200 dilution)
RRID #:AB_10013803
AntibodyAnti-Rhodopsin (α-Rho; 1d1)
Mouse monoclonal - 1:100 dilution
ZDB-ATB-081229–13
AntibodyAb-4C12 (aka, 4C12)
Mouse monoclonal - 1:50: dilution
ZDB-ATB-090506–2
AntibodyAnti-Mouse IgG (H+L), Alexa 647
Goat polyclonal - 1:1000 dilution
RRID #:AB_2338902
AntibodyAnti-Cone Arrestin (mouse)
Rabbit polyclonal - 1:1000 dilution
RRID #:AB_1163387
AntibodyAnti-Retinal S antigen (S128)
Mouse monoclonal - 1:1000 dilution
RRID #:AB_2747776
AntibodyAnti-PAR (human)
Recombinant Antibody - 1:2000 dilution
PMID:30385548
AntibodyAnti-Human IgG (Fab')2 (HRP)
Goat polyclonal - 1:10000 dilution
RRID #:AB_1951105
AntibodyAnti-beta-Actin-HRP
Mouse monoclonal - 1:20000 dilution
RRID #:AB_262011
Chemical compound17-(Allylamino)−17-demethoxygeldanamycin (17-AAG)CAS #: 75747-14-7
Chemical compound17β-EstradiolCAS #: 50-28-2
Chemical compound3-Hydroxybenzylhydrazine dihydrochlorideCAS #: 81012-99-9
Chemical compound6,7-DihydroxyflavoneCAS #: 38183-04-9
Chemical compoundAcacetinCAS #: 480-44-4
Chemical compoundAc-DEVD-CHO (AC)CAS #: 169332-60-9
Chemical compoundAG-14361CAS #: 328543-09-5
Chemical compoundAlpha-lipoic acidCAS #: 1077-28-7
Chemical compoundAlpha-tochopherolCAS #: 10191-41-0
Chemical compoundAluminum chloride hexahydrateCAS #: 7784-13-6
Chemical compoundArtemisinin (ART)CAS #: 63968-64-9
Chemical compoundAscorbic acidCAS #: 50-81-7
Chemical compoundCalcimycin (CAL)CAS #: 52665-69-7
Chemical compoundCalpastatin peptidesigmaaldrich.com: SCP0063
Chemical compoundCalpeptinCAS #: 117591-20-5
Chemical compoundCaspase-3 Inhibitor VII (CASVII)CAS #: 745046-84-8
Chemical compoundCaspase-3/7 Inhibitor I (CASI)CAS #: 1110670-49-9
Chemical compoundChloroxine (CHL)CAS #: 773-76-2
Chemical compoundCiclopirox olamine (CPO)CAS #: 41621-49-2
Chemical compoundClonidineCAS #: 4205-90-7
Chemical compoundClopidogrel sulfateCAS #: 120202-66-6
Chemical compoundCloxyquine (CLO)CAS #: 130-16-5
Chemical compoundCompactinCAS #: 73573-88-3
Chemical compoundCortexolone (COR)CAS #: 152-58-9
Chemical compoundD-(-)-NorgestrelCAS #: 797-63-7
Chemical compoundDanthronCAS #: 117-10-2
Chemical compoundDAPI dihydrochlorideCAS #: 28718-90-3
Chemical compoundDeltalineCAS #: 6836-11-9
Chemical compoundDexamethasoneCAS #: 50-02-2
Chemical compoundDiazepamCAS #: 439-14-5
Chemical compoundDigoxinCAS #: 20830-75-5
Chemical compoundDihydroartemisininCAS #: 71939-50-9
Chemical compoundE7449CAS #: 1140964-99-3
Chemical compoundEntinostatCAS #: 209783-80-2
Chemical compoundEscitalopram oxalateCAS #: 219861-08-2
Chemical compoundEupatorinCAS #: 855-96-9
Chemical compoundHoechst 33342CAS #: 23491-52-3
Chemical compoundHydroquinoneCAS #: 123-31-9
Chemical compoundIndomethacinCAS #: 53-86-1
Chemical compoundIsopropamide IodideCAS #: 71-81-8
Chemical compoundIsoxsuprine hydrochlorideCAS #: 579-56-6
Chemical compoundLactuloseCAS #: 4618-18-2
Chemical compoundLeucovorin CalciumCAS #: 1492-18-8
Chemical compoundLevobetaxololCAS #: 93221-48-8
Chemical compoundLobeline sulfateCAS #: 134-64-5
Chemical compoundLovastatinCAS #: 75330-75-5
Chemical compoundMagnesium gluconateCAS #: 3632-91-5
Chemical compoundMenadioneCAS #: 58-27-5
Chemical compoundMercaptamine hydrochlorideCAS #: 156-57-0
Chemical compoundMethyl-3,4-dephostatin (MD)PubChem SID #: 24278575
Chemical compoundMetronidazole (MTZ)CAS #: 443-48-1
Chemical compoundMiconazole (MIC)CAS #: 22916-47-8
Chemical compoundMnTBAPCAS #: 55266-18-7
Chemical compoundMyriocinCAS #: 35891-70-4
Chemical compoundMyrrh oilUPC #: 640791683602
Chemical compoundN-Acetyl-L-cysteine (NAC)CAS #: 616-91-1
Chemical compoundNalidixic acidCAS #: 389-08-2
Chemical compoundNCS-382CAS #: 520505-01-5
Chemical compoundNecrostatin-1 (NET)CAS #: 4311-88-0
Chemical compoundNiraparib (MK)CAS #: 1038915-60-4
Chemical compoundNMS-P118CAS #: 1262417-51-5
Chemical compoundN-tert-Butyl-α-(2-sulfophenyl)nitroneCAS #: 73475-11-3
Chemical compoundOlaparib (OLA)CAS #: 763113-22-0
Chemical compoundPanobinostatCAS #: 404950-80-7
Chemical compoundParomomycin (PM)CAS #: 1263-89-4
Chemical compoundPLGACAS #: 26780-50-7
Chemical compoundPseudoephedrine, (1S,2S)-(+)-CAS #: 90-82-4
Chemical compoundRetinoic acid (RA)CAS #: 302-79-4
Chemical compoundRofecoxibCAS #: 162011-90-7
Chemical compoundRomidepsinCAS #: 128517-07-7
Chemical compoundRosiglitazoneCAS #: 122320-73-4
Chemical compoundRucaparib (RUC)CAS #: 283173-50-2
Chemical compoundStreptomycin sulfateCAS #: 3810-74-0
Chemical compoundSulindac (SUL)CAS #: 38194-50-2
Chemical compoundSunitinibCAS #: 557795-19-4
Chemical compoundTalazoparib (BMN)CAS #: 1207456-01-6
Chemical compoundthapsigarginCAS #: 67526-95-8
Chemical compoundThiostrepton (ThS)CAS #: 1393-48-2
Chemical compoundtunicamycinCAS #: 11089-65-9
Chemical compoundVeliparib (ABT)CAS #: 912444-00-9
Chemical compoundVorinostatCAS #: 149647-78-9
Chemical compoundWarfarin (WAR)CAS #: 81-81-2
Chemical compoundXanthurenic acidCAS #: 59-00-7
Chemical compoundZinc pyrithione (ZPT)CAS #: 13463-41-7
Software, algorithmSoftware for large-scale in vivo screen data processing (R v3.3.1, R Studio v0.99.903, and the ARQiv2 package)https://github.com/mummlab/ARQiv2
Software, algorithmThermo Scientific HCS Studio Cell Analysis SoftwareCustomized for this project
DatabaseCRISPRScanhttps://www.crisprscan.org/

Additional files

Supplementary file 1

Statistics of Mtz titration assay.

(a) Statistical summary of Mtz titration assay in rho:YFP-NTR zebrafish larvae - Figure 1B. Survival effects (normalized YFP, %), 95% confidence intervals, p-values, and sample sizes (N) for each condition at 7 dpf. Student’s t-test was used to calculate p-values for each condition relative non-ablated controls (0 mM Mtz). Bonferroni correction for multiple comparisons resulted in an adjusted alpha level of 0.01 (α=0.01). Two experimental repeats were performed for each condition and data pooled across replicates (Figure 1—source data 1). (b) Paired compound p-values relative to all control conditions in Figure 7—figure supplement 1. Student’s t-test was used to calculate p-values for each paired condition relative to ablated controls (+Mtz), BMN alone control and NEC alone control for all paired conditions. Bonferroni correction for multiple comparisons resulted in an adjusted significance level of 0.003 (α=0.003). Survival effects as shown in Figure 7—figure supplement 1 are provided for context (Figure 7—figure supplement 1—source data 1). Inhibitor abbreviations: BMN, talazoparib; NEC, necrostatin-1. Other abbreviations: CI, confidence interval; Mtz, Metronidazole; NA, not applicable. (c) Paired compound p-values relative to all control conditions in Figure 10. Student’s t-test was used to calculate p-values for each paired condition relative to ablated controls (+Mtz) and relevant individual compound controls (Cmpd A, top paired compound; Cmpd B, bottom paired compound). Bonferroni correction for multiple comparisons to +Mtz control resulted in an adjusted significance level of 0.002 (α=0.002); significance level for comparisons to individual compound controls was 0.05 (α=0.05). Survival effects as shown in Figure 10 are provided for context (Figure 10—source data 1). Lead compound abbreviations: WAR, Warfarin; CLO, Cloxyquin; CPO, Ciclopirox olamine; MIC, Miconazole; ZPT, Zinc pyrithione; DHA, Dihydroartemisinin; CHL, Chloroxine; CAL, Calcimycin; SUL, Sulindac; ART, Artemesinin; COR, Cortexolone; POS, positive control. Other abbreviations: CI, confidence interval; Mtz, Metronidazole.

https://cdn.elifesciences.org/articles/57245/elife-57245-supp1-v4.xlsx
Supplementary file 2

Previously implicated neuroprotectants.

(a) Compounds tested as positive controls. List of 17 compounds previously reported as neuroprotectants in RP models tested for survival effects in rho:YFP-NTR zebrafish larvae using the primary screening protocol. (b) List of eliminated compounds. Compounds that were autofluorescent (precluding YFP signal detection) or lethal at the concentrations tested (10 mM to 0.625 mM). (c) List of 113 hit compounds. Hit compounds producing a SSMD score ≥1 in the primary screen ordered according to SSMD score. Drug names, concentrations producing SSMD ≥1, SSMD scores, SSMD effect types, and whether a dose-dependent trend was observed or not are shown. Yellow highlighted drugs were selected for confirmation testing. ‘'●” denotes confirmed lead compounds (source data). (d) On-label MOA for 113 hit compounds. Implicated MOA categories and subcategories are listed in order from most common to least common. The number of compounds per each category/subcategory are provided in the parentheses and compound names are listed.

https://cdn.elifesciences.org/articles/57245/elife-57245-supp2-v4.docx
Supplementary file 3

Oligonucleotides used for sgRNA synthesis (gene knockdown) and qPCR primers.

Abbreviations: parp1, poly (ADP-ribose) polymerase 1; ripk1l, receptor (TNFRSF)-interacting serine-threonine kinase 1, like; casp3a: caspase 3, apoptosis-related cysteine peptidase a; casp3b: caspase 3, apoptosis-related cysteine peptidase b; tdp1, tyrosyl-DNA phosphodiesterase 1; actb1: actin, beta 1; rplp0: ribosomal protein, large, P0.

https://cdn.elifesciences.org/articles/57245/elife-57245-supp3-v4.docx

Download links